This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

Please read this guide carefully and use it when prescribing KANUMA® as it contains essential safety and efficacy information. The guide was created as part of the KANUMA® Risk Management Plan and includes risk-minimising measures for the safe and effective use of this medicinal product. The guide is a mandatory part of the approval process for KANUMA®, to help ensure that healthcare professionals take into account the special safety requirements of prescribing this medicinal product.

Dear Healthcare Professional Communication related to risk of medication errors associated with overdose for Keppra Oral solution.

Checklist for the prescriber: Minimising the risk of photosensitivity with topical ketoprofen

Information sheet for patients: Minimising the risk of skin reactions with topical ketoprofen

This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with KEVZARA For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected] .

Short description of latest update of the Keytruda Materials

The risk minimisation materials for pembrolizumab were developed as a condition of the marketing authorisation grant for this product. The patient alert card should be issued to and carried by patients being treated with pembrolizumab and provides important safety information to minimise the risk of immune-related adverse reactions. In addition it contains emergency contact details for the patient and their specialist,

The information in this brochure is for patients who are being given tebentafusp. It is administered by your doctor. Your doctor will also talk with you about this brochure and important information for you like the benefits and the risks of tebentafusp therapy and what to expect regarding your monitoring schedule.

The information in this brochure is for patients who are being given tebentafusp. It is administered by your doctor. Your doctor will also talk with you about this brochure and important information for you like the benefits and the risks of tebentafusp therapy and what to expect regarding your monitoring schedule.

Important information about ▼KIMMTRAK® (tebentafusp) Information to assist healthcare professionals: • Description of Cytokine Release Syndrome (CRS) and Acute Skin Reactions in patients treated with tebentafusp, including severity, frequency, time to onset, treatment, and resolution. • How to manage CRS and acute skin reactions based on severity grade including information when corticosteroid premedication is recommended. • Monitoring requirements for patients during the first three infusions and for subsequent infusions. • How to minimise the risk of hypotension associated with CRS. • Description of the ECG schedule and management requirements based on the ECG results. • Recommendation to carefully monitor patients with cardiac disease, QT prolongation and risk factors for cardiac failure. • Information on the importance of informing patients of the risk of CRS and Acute Skin Reactions, and the need to immediately contact their doctor or nurse if they develop any symptoms of CRS or Acute Skin

The material above is available for Kineret when used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Mediterrranean Fever (FMF) and Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD).

The material above is available for Kineret when used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Mediterranean Fever (FMF) and Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD).

Abacavir Hypersensitivity Website for Healthcare Professionals

Healthcare professional brochure to describe risk of ectopic pregnancy and how to differentiate between Bayer levonorgestrel IUS (LNG-IUS)

Training on risks and management of CRS and neurological events, patient education and adverse event reporting

Alert card to be carried by patients

Information for patients and caregivers

Pharmacy / Cell Lab / Infusion centre training material on steps for reception, storage, handling and preparation for infusion